KaliVir Immunotherapeutics

Multiple therapies, one virus.

Pittsburgh, United States · Founded 2019 · $14.0M raised

Employees
11–50
Founded
2019
Business Model
B2B
Total Funding
$14.0M
Last Round
$14.0M Extension RoundAug 2026
Rounds
1

About

KaliVir Immunotherapeutics is a clinical-stage biotechnology company developing next-generation oncolytic viral immunotherapy programs for the treatment of cancer. Founded in 2019, the company's proprietary Vaccinia Enhanced Template (VET) platform enables the engineering of oncolytic vaccinia viruses capable of systemic IV delivery, targeting solid tumors with multi-mechanistic anti-tumor effects. KaliVir has active clinical collaborations with major pharmaceutical partners including Astellas and Roche, and its lead program VET3-TGI is entering Phase 1 trials in combination with Roche's atezolizumab for advanced solid tumors.

Summary

KaliVir Immunotherapeutics is a Biotech company based in Pittsburgh, United States, founded in 2019. It has raised $14.0M in total across 1 round, most recently a $14.0M Extension Round round in Aug 2026.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundSeries A ExtensionAug 2026
$14.0M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

KaliVir Immunotherapeutics on Indexed.vc
<a href="https://indexed.vc/companies/kalivir-immunotherapeutics"><img src="https://indexed.vc/api/badge/company/kalivir-immunotherapeutics" alt="KaliVir Immunotherapeutics on Indexed.vc" width="260" height="76" /></a>